(Q36761358)

16 August 2017

1 reference

title

Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (English)

1 reference

16 August 2017

2

Frank Ruschitzka

1 reference

16 August 2017

Matthias Hermann

1

1 reference

PubMed ID

17364448

16 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

39

1 reference

16 August 2017

1

1 reference

16 August 2017

18-27

1 reference

Cyclooxygenase-2 inhibition and cardiovascular events

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Relationship between COX-2 specific inhibitors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Non-narcotic analgesic dose and risk of incident hypertension in US women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890601073445

10.1080/07853890601073445

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17364448